MX2017004476A - Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion. - Google Patents
Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion.Info
- Publication number
- MX2017004476A MX2017004476A MX2017004476A MX2017004476A MX2017004476A MX 2017004476 A MX2017004476 A MX 2017004476A MX 2017004476 A MX2017004476 A MX 2017004476A MX 2017004476 A MX2017004476 A MX 2017004476A MX 2017004476 A MX2017004476 A MX 2017004476A
- Authority
- MX
- Mexico
- Prior art keywords
- powder
- composition
- weight
- stability
- dry powder
- Prior art date
Links
- 239000000843 powder Substances 0.000 title abstract 11
- 239000000203 mixture Substances 0.000 title abstract 6
- 238000009472 formulation Methods 0.000 title abstract 2
- 238000001694 spray drying Methods 0.000 title 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 3
- 239000008101 lactose Substances 0.000 abstract 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000010419 fine particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
La presente invencion se refiere a formulaciones de inhalacion de farmacos en forma de polvo seco para administracion por inhalacion, que se pueden suministrar como tales con un inhalador y proporcionan alta capacidad de liberacion, respirabilidad y estabilidad. En particular, la invencion se refiere a una composicion farmaceutica para uso por inhalacion en forma de polvo que comprende un primer polvo que comprende al menos un polvo (a1) que comprende un agente activo o una sal farmacéuticamente aceptable del mismo, n una cantidad mayor a 1% en peso del polvo, leucina en una cantidad del 5 al 70% en peso de dicho polvo, un azucar en una cantidad del 20 al 90% en peso del polvo; y un segundo polvo que comprende una mezcla de una primera lactosa que tiene un X50 de 35 a 75 um, con una segunda lactosa que tiene un X50 de 1.5 a 10 um, el contenido de las primera y segunda lactosas en la mezcla es del 85% al 96% y del 4% al 15% respectivamente. La relación en peso entre el primer polvo y el segundo polvo es de 1/5 a 1/100, y la composicion tiene una fraccion de partículas finas (FPF) superior al 60% y una fraccion entregada (DF) superior al 85%.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI20141761 | 2014-10-08 | ||
| PCT/EP2015/073188 WO2016055544A1 (en) | 2014-10-08 | 2015-10-07 | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017004476A true MX2017004476A (es) | 2017-11-20 |
| MX375427B MX375427B (es) | 2025-03-06 |
Family
ID=51904067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017004476A MX375427B (es) | 2014-10-08 | 2015-10-07 | Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10517828B2 (es) |
| EP (1) | EP3203983A1 (es) |
| JP (1) | JP6919093B2 (es) |
| KR (1) | KR102462058B1 (es) |
| CN (1) | CN107205936B (es) |
| AU (2) | AU2015330010A1 (es) |
| CA (1) | CA2962531C (es) |
| CO (1) | CO2017004504A2 (es) |
| EA (1) | EA035740B1 (es) |
| IL (1) | IL251472B (es) |
| MX (1) | MX375427B (es) |
| MY (1) | MY191712A (es) |
| WO (1) | WO2016055544A1 (es) |
| ZA (1) | ZA201703125B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2929818T3 (es) | 2020-05-18 | 2022-12-02 | Orexo Ab | Nueva composición farmacéutica para la administración de fármacos |
| EP4203928A4 (en) * | 2020-08-26 | 2024-10-09 | Cila Therapeutic Inc. | Inhalable therapeutic agents |
| CN112125818A (zh) * | 2020-09-23 | 2020-12-25 | 山东瑞博龙化工科技股份有限公司 | 一种制备n,n-二乙基丙烯酰胺的系统及工艺 |
| IT202000030437A1 (it) * | 2020-12-10 | 2022-06-10 | Zambon Spa | Metodo per la realizzazione di una polvere inalabile comprendente voriconazolo |
| GB202117016D0 (en) | 2021-11-25 | 2022-01-12 | Orexo Ab | New pharmaceutical device |
| IL313016A (en) | 2021-11-25 | 2024-07-01 | Orexo Ab | A pharmaceutical preparation that includes adrenaline |
| CN115400103B (zh) * | 2022-09-22 | 2023-11-24 | 苏州易合医药有限公司 | 一种多孔性呼吸颗粒及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9826783D0 (en) * | 1998-12-04 | 1999-01-27 | Scherer Ltd R P | Inhalation powders |
| GB0009584D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Pharmaceutical compositions |
| WO2002000197A1 (en) * | 2000-06-27 | 2002-01-03 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
| US8337816B2 (en) * | 2001-09-17 | 2012-12-25 | Glaxo Group Limited | Dry powder medicament formulations |
| US20040204439A1 (en) * | 2003-04-14 | 2004-10-14 | Staniforth John Nicholas | Composition, device, and method for treating sexual dysfunction via inhalation |
| ITMI20051999A1 (it) * | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
| CA2677347A1 (en) * | 2007-02-09 | 2008-08-14 | Jill K. Sherwood | Stable pharmaceutical drug aerosols |
| WO2011069197A1 (en) * | 2009-12-08 | 2011-06-16 | The University Of Sydney | Inhalable formulations |
| GB201102237D0 (en) * | 2011-02-09 | 2011-03-23 | Kuecept Ltd | Particle formulation |
| KR101539158B1 (ko) * | 2011-03-02 | 2015-07-23 | 니뽄 다바코 산교 가부시키가이샤 | 끽연 물품용 향료 함유 시트의 제조방법, 그 방법에 의해 제조되는 끽연 물품용 향료 함유 시트, 및 그것을 포함하는 끽연 물품 |
| EP2804585A1 (en) * | 2012-01-16 | 2014-11-26 | Mahmut Bilgic | Dry powder formulations comprising tiotropium, formoterol and budesonide |
| RS63759B1 (sr) | 2012-01-25 | 2022-12-30 | Chiesi Farm Spa | Formulacija suvog praha koja sadrži kortikosteroid i beta-adrenergik, za primenu inhalacijom |
| EA036153B1 (ru) * | 2012-07-05 | 2020-10-06 | Арвен Айлак Санайи Ве Тиджарет А.С. | Фармацевтическая композиция для ингаляции, упакованная дозированная форма, капсула, способ лечения обструктивных заболеваний дыхательных путей и фармацевтический набор |
-
2015
- 2015-10-07 EP EP15784293.1A patent/EP3203983A1/en active Pending
- 2015-10-07 JP JP2017519565A patent/JP6919093B2/ja active Active
- 2015-10-07 MX MX2017004476A patent/MX375427B/es active IP Right Grant
- 2015-10-07 EA EA201700182A patent/EA035740B1/ru unknown
- 2015-10-07 KR KR1020177012212A patent/KR102462058B1/ko active Active
- 2015-10-07 MY MYPI2017701171A patent/MY191712A/en unknown
- 2015-10-07 CN CN201580054325.0A patent/CN107205936B/zh active Active
- 2015-10-07 AU AU2015330010A patent/AU2015330010A1/en not_active Abandoned
- 2015-10-07 WO PCT/EP2015/073188 patent/WO2016055544A1/en not_active Ceased
- 2015-10-07 CA CA2962531A patent/CA2962531C/en active Active
- 2015-10-07 US US15/517,689 patent/US10517828B2/en active Active
-
2017
- 2017-03-30 IL IL251472A patent/IL251472B/en unknown
- 2017-05-04 CO CONC2017/0004504A patent/CO2017004504A2/es unknown
- 2017-05-05 ZA ZA2017/03125A patent/ZA201703125B/en unknown
-
2021
- 2021-01-27 AU AU2021200503A patent/AU2021200503B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170093114A (ko) | 2017-08-14 |
| MY191712A (en) | 2022-07-09 |
| BR112017007182A2 (pt) | 2017-12-19 |
| WO2016055544A1 (en) | 2016-04-14 |
| JP2017530993A (ja) | 2017-10-19 |
| AU2021200503A1 (en) | 2021-02-25 |
| US20170333349A1 (en) | 2017-11-23 |
| EA035740B1 (ru) | 2020-08-03 |
| JP6919093B2 (ja) | 2021-08-18 |
| US10517828B2 (en) | 2019-12-31 |
| MX375427B (es) | 2025-03-06 |
| IL251472B (en) | 2021-08-31 |
| CN107205936B (zh) | 2021-07-16 |
| CA2962531C (en) | 2023-05-23 |
| EA201700182A1 (ru) | 2017-09-29 |
| IL251472A0 (en) | 2017-05-29 |
| CA2962531A1 (en) | 2016-04-14 |
| AU2021200503B2 (en) | 2023-01-12 |
| AU2015330010A1 (en) | 2017-04-27 |
| KR102462058B1 (ko) | 2022-11-01 |
| EP3203983A1 (en) | 2017-08-16 |
| ZA201703125B (en) | 2020-05-27 |
| CO2017004504A2 (es) | 2017-10-20 |
| CN107205936A (zh) | 2017-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY175781A (en) | Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation | |
| MX2017004476A (es) | Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion. | |
| TN2015000395A1 (en) | Respirable agglomerates of porous carrier particles and micronized drug | |
| WO2015120110A3 (en) | Novel pharmaceutical formulations | |
| MX382192B (es) | Composiciones de canabinoide y usos. | |
| WO2012143576A3 (en) | Compounds for preventing, reducing and/or alleviating itchy skin condition(s) | |
| HK1203149A1 (en) | Novel dosage form and formulation of abediterol | |
| PH12012502404A1 (en) | Dry powder formulation comprising an antimuscarinic drug | |
| NZ627837A (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
| MX2015014513A (es) | Composicion que comprende sulfato de salbutamol. | |
| BR112015027017A2 (pt) | composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas | |
| BR112015020443A8 (pt) | formulação em pó para inalação, seus usos e seu processo de preparação, e composição farmacêutica | |
| HK1215167A1 (zh) | 可吸入药用组合物和含有该药用组合物的吸入器装置 | |
| AU2014226192A8 (en) | Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles | |
| WO2011093815A3 (en) | Pharmaceutical compositions comprising formoterol and mometasone | |
| WO2014167579A3 (en) | Stable pharmaceutical compositions of tadalafil | |
| MY187442A (en) | A pharmaceutical composition containing budesonide and formoterol | |
| WO2011093811A3 (en) | Pharmaceutical preparations comprising formoterol and fluticasone | |
| MY191295A (en) | Pharmaceutical composition containing budesonide and formoterol | |
| WO2011093812A3 (en) | Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form | |
| BR112017021111A2 (pt) | processo para fabricação de misturas de pós secos | |
| WO2011093810A3 (en) | Dry powder pharmaceutical composition comprising tiotropium and mometasone | |
| NZ731059B2 (en) | An inhalable rapamycin formulation for the treatment of pulmonary hypertension | |
| NZ731059A (en) | An inhalable rapamycin formulation for the treatment of pulmonary hypertension | |
| TH159392A (th) | สูตรผสมผงแห้งที่ประกอบรวมด้วยแอนติโคลิเนอร์จิก, คอร์ติโคสเตียรอยด์ และเบตา-แอดรีเนอร์จิกสำหรับการให้โดยการสูด |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| PD | Change of proprietorship |
Owner name: ZAMBON S.P.A. |